Determining the right prostate cancer treatment for you
Following a cancer diagnosis, it’s natural to feel overwhelmed, making it challenging to decide on the right treatment option. Many people report feeling lost about next steps and a need for deeper education about their options.
The ArteraAI Prostate Test is an artificial intelligence precision medicine test, designed to help clinicians and patients come to a shared decision on the optimal personalized treatment plan.
Where does the ArteraAI Prostate test fit in the patient journey?
The test is designed to support clinical decision-making through risk stratification, determining suitability for active surveillance, and prediction of ST-ADT benefit for patients with localized prostate cancer.
How the ArteraAI Prostate Test helps
Recommended in NCCN Guidelines
Multimodal AI (ArteraAI Prostate Test) has undergone rigorous validation and is supported by trusted entities in cancer care, including the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer.Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.4.2024. ©National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed June 4, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. NCCN, National Comprehensive Cancer Network.
Fast turnaround with no additional procedures
The ArteraAI Prostate Test does not require any additional procedures because it uses the digitized image of a patient's existing tissue sample. Results can be shared within 1-2 days after receipt of the patient's histopathology slide.
Financial options available
Medicare (CMS) has established a payment rate for the ArteraAI Prostate Test. Artera also offers a financial assistance program for patients covered by commercial insurance and may have large out-of-pocket costs.
Minimizing the side effects of unnecessary treatment during cancer care
Hormone therapy, also called androgen deprivation therapy (ADT), is often used with radiation therapy in prostate cancer care. However, not everyone will benefit equally from ADT, and the treatment can come with significant side effects, including fatigue, sexual dysfunction, cognitive changes, and metabolic concerns.
The ArteraAI Prostate Test provides personalized insight into whether ADT is likely to help in your situation, whether you are newly diagnosed or have had prostate surgery and your PSA is rising again. This information can help you and your doctor make a personalized plan for your cancer care.
How one patient found peace of mind with ArteraAI
“I was looking for a treatment that could give me a better quality of life by minimizing the side effects….the ArteraAI Prostate Test revealed that I could avoid ADT and my treatment went well. I’m very glad I was able to avoid ADT.”
ArteraAI Prostate Test Guide 2025
This test is for patients who have been diagnosed with localized prostate cancer who have not yet received radiation therapy.
Mind the Gap
While all men are at risk for prostate cancer, there are disproportionate gaps in treatment, research, clinical trials and mortality rates among African American men that need to be recognized and can be addressed with the aid of AI
Plain Language Summary
This summary is for anyone who wants to learn more about tools that help determine treatment in men with prostate cancer.
ArteraAI Prostate Test Brochure
This brochure provides more information about how the ArteraAI Prostate Test works.
Frequently asked questions
Explore our FAQ section to find straightforward answers to your questions about the ArteraAI Prostate Test.
The ArteraAI Prostate Test is available to men at three key moments:
- When they are first diagnosed with localized prostate cancer and are deciding on their initial treatment, and
- After surgery, if their PSA begins to rise and are considering additional treatment
Your doctor can determine whether the biopsy or post-RP test is right for you.
The out-of-pocket cost for the ArteraAI Prostate Test will be based on your insurance plan. If you are covered by Medicare Plan B, you should have zero out-of-pocket costs for the ArteraAI Prostate Test. If you are covered by private insurance, financial liability will be subject to the terms of your plan taking into consideration copays, coinsurance and deductibles. You should contact billing@artera.ai for additional details about the estimated out-of-pocket liability for the test.
The ArteraAI Prostate Test results are typically ready within 1-2 days after receipt of the patient’s specimen in our CLIA-certified lab. The clinician can access the patient’s report via an online portal or have it faxed.
The ArteraAI Prostate Test provides personalized information about how your cancer might behave and which treatments are most likely to help you, whether you’ve been diagnosed with early or later stage prostate cancer. This includes risk scores for cancer spreading or coming back, and guidance on treatments like hormone therapy, chemotherapy, or active surveillance. This information helps you and your doctor make treatment decisions that are right for your specific situation.
The ArteraAI Prostate Test does not require any additional procedures, as it relies on your existing tissue sample. The test also does not consume any tissue so it will not impact the ability to run additional tests that may need to consume tissue.
The ArteraAI Prostate Test has undergone rigorous validation. The algorithm has been developed using large sets of data, from thousands of patients and tens of thousands of pathology slide images (digitally scanned tissue slides) and has been clinically validated using many Phase 3 randomized trials. Multiple Phase 3 randomized trials with up to 15-year follow-ups were used to develop and validate the prognostic and predictive AI models.
The ArteraAI Prostate Test can offer insights into your prostate cancer and more clarity around your optimal treatment path, allowing you to engage in informed shared decision-making with your clinician.
The ArteraAI Prostate Test uses existing tissue slides and does not consume tissue or require additional procedures. As there are no additional medical procedures required for this test, there are no side effects or complications to be concerned about.
The ArteraAI Prostate Test is available as part of Artera’s CLIA-certified laboratory developed test (LDT) service. This test has not been cleared nor approved by the FDA.
Be your own advocate! Share this information with your doctor today. Send to doctor
